mac

Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5

Emactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has antitumor activity and inhibits activation of colony-stimulating factor 1 receptor (CSF1R) Emactuzumab has a high affinity for CSF-1R with a Ki value of 0.2 nM. Emactuzumab blocks CSF-1R dimerization and can be used to study cancers such as diffuse tenosynovial giant cell tumor (dt-GCT).

Nimacimab is a recombinant humanized monoclonal antibody. It can improve diabetes and non-alcoholic steatohepatitis.

Abciximab (C7E3) is a mouse human chimeric monoclonal antibody that is a potent glycoprotein IIb IIIa inhibitor. Abciximab has anti-platelet aggregation and leukocyte adhesion, acting by binding to glycoproteins IIb IIIa, vitronectin and Mac-1 receptors.